Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. (CRL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
crl · pe ratio · data through Dec 27, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Charles River Laboratories International, Inc. (CRL) measures how much investors pay for each dollar of the company's trailing earnings. CRL's current PE ratio of N/A is calculated by dividing its stock price of $185.52 by its TTM earnings per share of -$3.77.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-27
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 16 fiscal years · Front-end computedMinQ1 · 25%24.8x
MedianQ3 · 75%928.9x
Max
At N/A, CRL's current P/E is lower than in 0% of its annual fiscal year readings over the past 16 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Diagnostics & Research · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Charles River Laboratories International, Inc.You CRL | $8.9B | N/A | — | -$3.77 |
 Avantor, Inc. AVTR | $6.7B | N/A | — | -$0.78 |
 Baxter International Inc. BAX | $10.0B | N/A | — | -$1.87 |
 Bio-Rad Laboratories, Inc. BIO | $8.0B | 10.87x | -64.6% | $27.87 |
 Caris Life Sciences, Inc. CAI | $4.7B | N/A | — | -$0.32 |
 DaVita Inc. DVA | $12.4B | 13.10x | -57.3% | $8.67 |
 Penumbra, Inc. PEN | $12.6B | 68.10x | +121.9% | $4.57 |
Industry Average 3 peers with valid PE | — | 30.69x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-27Latest FY2025 | — | $-2.91 | — | |
2024-12-28 FY2024 | 928.90x | $0.20 | +3540.6% | |
2023-12-31 FY2023 | 25.52x | $9.27 | +12.0% | |
2022-12-31 FY2022 | 22.77x | $9.57 | -53.0% | |
2021-12-31 FY2021 | 48.47x | $7.77 | +42.6% | |
2020-12-31 FY2020 | 33.98x | $7.35 | +15.1% | |
2019-12-31 FY2019 | 29.54x | $5.17 | +23.2% | |
2018-12-31 FY2018 | 23.97x | $4.72 | -43.1% | |
2017-12-31 FY2017 | 42.13x | $2.60 | +82.0% | |
2016-12-31 FY2016 | 23.14x | $3.29 | -7.5% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Charles River Laboratories International, Inc. (CRL) measures how much investors pay for each dollar of the company's trailing earnings. CRL's current PE ratio of N/A is calculated by dividing its stock price of $185.52 by its TTM earnings per share of -$3.77.
Frequently asked questions
CRL pe ratio · 6 questionsCRL's current PE ratio is N/A as of 2026-06-08, based on a stock price of $185.52 and TTM EPS of -$3.77. Data sourced from Financial Modeling Prep via CRL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Charles River Laboratories International, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08